Completed PHASE2 INTERVENTIONAL 3-arm NCT04944706

Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction

Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction: a Randomized, Double-blind, Basic-treatment-loading, Placebo-controlled, Multicenter Phase Ⅱ Clinical Trial

Sponsor: Tasly Pharmaceutical Group Co., Ltd

Conditions Chronic Heart Failure With Preserved Ejection Fraction

Interventions Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time Qishen Yiqi dripping pills 4 bags/time Qishen Yiqi dripping pills placebo 4 bags/time

Updated 9 times since 2021 Last updated: Jan 8, 2025 Started: Jul 27, 2021 Primary completion: Dec 19, 2024 Completion: Dec 19, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Chronic Heart Failure With Preserved Ejection Fraction, this trial is completed. The trial is conducted by Tasly Pharmaceutical Group Co., Ltd and has accumulated 9 data snapshots since 2021. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Feb 2025 — Sep 2025 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Oct 2024 — Feb 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2

▶ Show 4 earlier versions

Sep 2023 — Jul 2024 [monthly]

Recruiting PHASE2
Dec 2022 — Sep 2023 [monthly]

Recruiting PHASE2
May 2022 — Dec 2022 [monthly]

Recruiting PHASE2
Sep 2021 — May 2022 [monthly]

Recruiting PHASE2

First recorded

Jul 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tasly Pharmaceutical Group Co., Ltd

Data source: Tasly Pharmaceutical Group Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Bengbu, China , Changchun, China , Changsha, China , Chongqing, China , Hohhot, China , Nanjing, China , Shijiazhuang, China , Taiyuan, China , Tianjin, China and 2 more locations